Private-equity executives have spent the past five years bemoaning the difficulty of investing profitably with stocks at elevated levels. Now, they’re getting a taste of what they wished for—and a whole new set of headaches.
Colleges and universities face unprecedented situations after the COVID-19 outbreak precipitated a mass exodus of students resulting in significant financial losses and a market downturn that is deeply affecting endowments.
Financial news outlets are full of predictions these days by investors who allegedly “called the coronavirus collapse” for what they think will happen next. A leaked client letter from a hedge fund star who made an absolute killing in the selloff promising a peak into his “magical crystal ball” is practically financial catnip.
Long-term investors like endowments and foundations are in a terrific position to capitalize on recent market volatility as the COVID-19 pandemic continues to unfold, according to experts at CAPTRUST Financial Advisors.
The coronavirus pandemic is throwing a spotlight on stocks in the U.S. healthcare sector, home to the companies that could develop treatments, vaccines and improved diagnostics needed to tackle the greatest public health crisis in a century.